In the post budget (S)EIS euphoria, we are excited to share some of the results from our recent survey from all of our 28 portfolio companies. The results are exciting given the size and longevity of our tax-efficient funds!
Our portfolio companies have together raised more than £230 million since their inception. Given the quanta we have invested in these companies, this demonstrates the interest that UK biotech companies generate globally.
Startups iin their early stages have the ability to expand employment opportunities and add new jobs to the economy. We are pleased to report that our portfolio companies have generated 425 or more job opportunities, and that is just the beginning!
50% of the companies in our portfolio are led by females by being either Founders, CEO’s or Chairs. The big kudos for this to these founders/entrepreneurs as this was not prescribed or contrived in any way by our Fund as all our investments are made purely on scientific/business merit.
We take great pride in announcing that 9 of our portfolio companies’ drug discoveries or related services will directly benefit patients in less than years, the other 9 in 3 to 7 years, and the remaining 8 companies within the next decade.
We are very proud of the impact that our portfolio companies have and the credit for this is to our hardworking, sometimes crazy founders/entrepreneurs. A big thank you from o2h Ventures!.
If you would like to know more about the funds, we can also arrange a call and provide further information, just send a short note to invest@o2h.com and we will schedule a call accordingly.
Our HMRC approved KI fund will close on October 31, 2022.
